• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Addiction Treatment Forum

Addiction Treatment Forum

Addiction Treatment Forum reports on substance use news of interest to opioid treatment programs and patients in medication-assisted treatment.

  • Newsletter
  • Addiction Resources
  • Methadone
  • Buprenorphine
  • Patient Brochures
  • Events
  • Related Websites

Kloxxado: Nasal Spray Naloxone Launched

August 16, 2021 by Alison Knopf

Kloxxado, approved by the Food and Drug Administration in April for treatment of opioid overdose (see https://atforum.com/2021/06/naloxone-nasal-spray/), is now officially on the market. And the timing is good; this naloxone 8-mg nasal spray, launched August 4 by manufacturer Hikma Pharmaceuticals, comes at a time when naloxone is in short supply. It is approved for both adult and pediatric patients.

Importantly, Kloxxado contains twice as much naloxone per spray as Narcan, which is important with so much illicit fentanyl causing difficult to reverse overdoses. Sometimes, first responders have to give two doses of the 4-mg Narcan spray. In addition, Narcan is in very short supply.

“Last year, fueled by the COVID-19 pandemic and the increasing prevalence of illicitly manufactured synthetic opioids, the number of Americans who died from a drug overdose rose by nearly 30% to more than 93,000, with approximately 75% of those deaths involving opioids,1” said Desiree Crevecoeur-MacPhail, Ph.D., Assistant Professor of Psychology, Chapman University and former Director of Quality Assurance and Utilization Management for the Los Angeles Centers for Alcohol and Drug Abuse, in press materials for Kloxxado. “There is an urgent need for additional resources to combat this epidemic, and Kloxxado will provide an important new tool for those on the front lines of this fight.”

“Naloxone has long been recognized as an important, safe and effective treatment in the fight against opioid overdose,2 but with the increasing prevalence of illicitly manufactured synthetic opioids, organizations including the CDC, the American Medical Association4 and others have noted that a higher dose of naloxone may be required to revive a patient due to their high potency,” said Daniel Buffington, PharmD, MBA, FAPhA, a clinical pharmacology specialist, President and Practice Director at Clinical Pharmacology Service and faculty member at the University of South Florida Colleges of Medicine and Pharmacy, also in press materials for Kloxxado. “As a ready-to-use nasal spray that contains twice as much naloxone per spray than the current standard of care, Kloxxado provides an important new treatment for those suffering from an opioid overdose.”  

In one survey, 34% of attempted overdose reversals with Narcan used two or more doses, and a separate study found that the percent of overdose calls requiring multiple doses had increased 43% during 2013-2016.

“We are committed to ensuring Kloxxado is widely accessible to all who can benefit from it, including patients, friends, family members and the public health community,” said Brian Hoffmann, President, Hikma Generics. “As an experienced provider of addiction therapy treatments and a leading producer of nasal sprays in the US, we are pleased to leverage our capabilities to deliver an important new tool in the fight against opioid overdose.”

Naloxone hydrochloride is an opioid antagonist that reverses opioid effects, including respiratory depression, sedation, and hypotension, by competing for the same receptor sites.

Filed Under: 2021, Newsletter

Primary Sidebar

Upcoming Events

NEW2022 AATOD Conference
October 30-November 3, 2022

https://www.eventscribe.net/2022/AATOD/

 

View More Upcoming Events…

ATForum.com

  • Newsletter
  • Addiction Resources
  • Rx Methadone & Safety
  • Patient Education Brochures
  • Events
  • Related Websites

Addiction Resources

  • Addiction and Recovery
  • Addiction Treatment Forum
  • Books and Booklets of Interest
  • Drug Screening and Testing
  • Evidence-Based Addiction Medicine
  • Federal Government
  • Health Care Reform
  • Hepatitis, HIV/AIDS
  • Medication-Assisted Treatment
  • Mental Health
  • Miscellaneous
  • Online Continuing Education Free Training Modules

Footer

Addiction Treatment Forum is produced by an independent medical communications agency. Commercial advertising is not accepted.
Published by Clinco Communications, Inc.
About Us
Contact Us
Privacy Policy
Terms of Use
Follow Us

This educational resource is supported by Hikma Pharmaceuticals USA Inc.

Sign up for News!

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Clinco Communications, Inc., 1808 N. Arlington Heights Road, Arlington Heights, IL, 60004, http://www.atforum.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

© 2022 Addiction Treatment Forum · All Rights Reserved